Glib Maznyi

Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy

J. Diallo, R. Arulanandam, Andrew Chen, 2022, Molecular therapy oncolytics.

Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen

J. Diallo, Stephen Boulton, S. Paludan, 2022, Molecular Therapy.

A New Functional Screening Platform Identifies Colistin Sulfate as an Enhancer of Natural Killer Cell Cytotoxicity

J. Diallo, Seung-Hwan Lee, M. Ardolino, 2022, Cancers.

A small molecule drug screening identifies colistin sulfate as an enhancer of Natural Killer cell cytotoxicity

J. Diallo, Seung-Hwan Lee, M. Ardolino, 2021, bioRxiv.

Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern

J. Diallo, J. van Grevenynghe, J. Hiscott, 2021, ACS infectious diseases.

Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines

J. Diallo, R. Auer, R. Arulanandam, 2022, Frontiers in Immunology.

Tepilamide Fumarate as a Novel Potentiator of Virus-Based Therapy

J. Diallo, R. Arulanandam, Andrew Chen, 2024, Viruses.